Showing 8 posts of 8 posts found.


Top Ten most popular articles on this week!

April 12, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, BMS, Eisai, Gilead, MSD, Pfizer, ViiV, indivior

This week was an excellent week for recommendations and approvals after Eisai, MSD, Pfizer, BMS and ViiV scored wins. Meanwhile …


Indivior shares fall by 70% after allegations of fraud

April 10, 2019
Research and Development Virginia, indivior, opioid crisis, opioids, suboxone

Shares in London-listed Indivior plummeted this morning after US Federal prosecutors said the British drugmaker had deceived doctors as to …


Dr Reddy’s demand more than $70 million from Indivior over generic Suboxone Film

March 12, 2019
Manufacturing and Production Dr Reddy's, Suboxone Film, court, indivior, opioid addiction

Indian firm Dr Reddy’s is seeking at least $70 million from British firm Indivior Plc as compensation for lost sales …


Indivior launches authorised generic version of opioid addiction treatment Suboxone as rival generic drugmakers enter market

February 21, 2019
Sales and Marketing Alvogen, Dr Reddy's, Novartis, Sandoz, indivior

Indivior has announced the launch of an authorised generic version of Suboxone Film (buprenorphine/naloxone) a combination medicine used to treat …


Indivior rocked by loss of patent case

March 23, 2018
Medical Communications, Sales and Marketing Alvogen, biotech, drugs, indivior, opioid, pharma, pharmaceutical

Indivior has been dealt a hammer blow after US District Court for the District of Delaware found in favour of …

Indivior’s opioid addiction treatment recommended by FDA advisory panel

November 1, 2017
Research and Development, Sales and Marketing FDA, RGP-6000, Trump, US, indivior, opioid crisis, opioids

Another step has been made in the fight back against the ongoing opioid crisis in the US as it emerges …


Indivior reaches settlement with Mylan over patent dispute

September 25, 2017
Sales and Marketing Mylan, indivior, patent, pharma, pharmaceutical, suboxone

Indivior has ended a patent dispute with Mylan concerning its heroin addiction therapy Suboxone (buprenorphine and naloxone) sublingual film by …

Reckitt image

Reckitt finalises pharmaceutical demerger plans

November 19, 2014
Business Services, Sales and Marketing Reckitt Benckiser Pharmaceuticals, cillit bang, indivior, suboxone

Reckitt Benckiser has confirmed its plans to spin-off its pharmaceutical portfolio from its core consumer products business. Final details of …

Latest content